NeuBase Therapeutics Inc at Chardan Genetic Medicines Conference (Virtual) Transcript
It's my pleasure to introduce our next guest from NeuBase Therapeutics, Chairman and CEO, Dietrich Stephan. The format for this session is a roughly 25 minute fireside chat. (Conference Instructions) So with that Dietrich, welcome. Could you please provide a couple of minutes of introductory comments about NeuBase for investors new to the story?
Sure, thanks again for having us at your conference this year. It's a real pleasure and always enjoy our conversations. So NeuBase Therapeutics is a genetic medicines company that is focused on drugging the genome to resolve root causality across a number of different diseases. And as you know this is a paradigm shift from the way we have historically developed drugs in our industry, drugging proteins through screening large chemical libraries and hoping that some of those chemicals stick and have the activity that we want without the toxicity and then engaging in what's often referred to as sort of a decade
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
